

April 28, 2025

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department  
Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting of the Company held on April 28, 2025**

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Monday, April 28, 2025, *inter-alia* considered and unanimously:

1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2025. A copy of the same is enclosed along with the Report of the Auditors thereon and a declaration stating that the said report is with unmodified opinion.
2. Recommended of final dividend of Rs. 20 (Rupees Twenty only) per equity share (250% on the face value of Rs.8 each) and additionally a special dividend of Rs. 4 (Rupees Four only) per equity share (50% on the face value of Rs. 8 each) on account of significant exceptional profit on assignment of land for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Approved the Audited Financial Statements of the Company, for the year ended March 31, 2025.
4. Based on recommendation of the Nomination and Remuneration Committee, approved appointment of Ms. Vasundhara Patni (DIN: 05015021), as an Additional Director in the capacity of Non-Executive Non-Independent Director of the Company w.e.f. April 28, 2025, subject to approval of shareholders at the ensuing Annual General Meeting and who shall be liable to retire by rotation. – Refer Annexure A.
5. Taken on record cessation of Mr. Yugal Sikri (DIN: 07576560), as the Managing Director of the Company on completion of his term at the end of business hours on April 30, 2025 – Refer Annexure B.
6. Based on recommendation of the Nomination and Remuneration Committee, approved continuation of Mr. Yugal Sikri (DIN: 07576560) on the Board by his appointment as a Non-Executive Non-Independent Director of the Company w.e.f. May 1, 2025, subject to approval of shareholders at the ensuing Annual General Meeting and who shall be liable to retire by rotation. – Refer Annexure C.
7. Taken on record cessation of Mr. Ashok Nair (DIN: 07906710) by resignation as a Senior Management Personnel of the Company at the end of business hours on April 30, 2025 – Refer Annexure D.
8. Based on recommendation of the Nomination and Remuneration Committee, approved appointment of Mr. Ashok Nair (DIN: 07906710) as an Additional Director in the capacity of Managing Director of the Company for a period

of 3 (three) years from May 1, 2025 to April 30, 2028, subject to approval of shareholders at the ensuing Annual General Meeting and who shall not be liable to retire by rotation. – Refer Annexure E.

**9. Reconstituted the following committees of the Board:**

<b>Sustainability and Corporate Social Responsibility Committee</b>			<b>Stakeholders' Relationship Committee</b>		
1.	Ms. Radhika Gupta	Chairperson	1.	Ms. Radhika Gupta	Chairperson
2.	Ms. Z. Khorakiwala	Member	2.	Mr. Anil Matai	Member
3.	Mr. Sachin Nandgaonkar	Member	3.	Mr. Ashok Nair	Member
4.	Mr. Ashok Nair	Member			

**10. Appointment of Secretarial Auditors:**

Based on the recommendations of the Audit Committee, approved appointment of M/s. Parikh Parekh & Associates, Practicing Company Secretaries, as the Secretarial Auditors of the Company for a period of 5 (five) consecutive years commencing from FY 2025-26 to FY 2029-30, subject to approval of the members of the Company at the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Part A of Schedule III and SEBI Master Circular dated November 11, 2024, as amended from time to time. - Refer Annexure F.

**11. Approved revision/change in the following Policy/Code:**

- Nomination and Remuneration Policy.
- Code of conduct for Board Members and Senior Management.

The aforesaid amended policy/code and above information shall be made available on the Company's website at <https://www.rpglifesciences.com/>.

The meeting commenced at 03:00 p.m. and concluded at 6.30 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

Rajesh Shirambekar  
Head – Legal & Company Secretary

**(Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015)**

**Annexure – A**

**1) Appointment of Ms. Vasundhara Patni (DIN: 05015021) as an Additional Non-Executive Non - Independent Director:**

1	Reason for Change viz. appointment, <del>reappointment, resignation, removal, death or otherwise</del>	Appointment as an Additional Director in the capacity of Non-Executive Non-Independent Director.
2	Date of Appointment/ <del>reappointment/cessation (as applicable) /reappointment/ term of appointment</del>	April 28, 2025
3	Brief Profile (in case of appointment)	<p>Mrs. Vasundhara Patni is a Mumbai based innovative entrepreneur and business leader with over 15 years of experience across consumer goods, early childhood education, and clean beauty. She is the Founder and CEO of Kiro Beauty, one of India's first clean, toxin-free, vegan makeup brands.</p> <p>Her entrepreneurial journey started with the launch of The Ice Stone Factory, India's first "fresh-made" cold slab ice cream dessert chain, where she also led brand development, retail expansion and customer experience strategy across multiple outlets in Mumbai. She ventured into the education sector, developing early childhood programs in collaboration with educators from Harvard, MIT, and other leading US universities. The programs were focused on cognitive, emotional and physical development strategies for young children.</p> <p>In August 2020, recognizing a need in the Indian beauty market for high-performance, toxin-free cosmetics, Vasundhara founded Kiro Beauty. The brand offers 100% vegan, cruelty-free, and paraben-free products, combining indulgence with intentionality. Kiro's product line includes over 120 SKUs, featuring skincare-infused makeup that caters to modern Indian women.</p> <p>she holds a Bachelor of Arts and Science from the University of Pennsylvania with a major in Communications.</p>

4	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Vasundhara Patni is daughter of Mr. Harsh V. Goenka, Chairman of the company.
5	Affirmation	As per declaration submitted to the Company, Ms. Vasundhara Patni has confirmed that she is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

### **Annexure – B**

#### **2) Cessation of Mr. Yugal Sikri (DIN: 07576560) as a Managing Director of the Company:**

1	Reason for Change viz. <del>Appointment, re-appointment, resignation, removal, death or otherwise;</del>	Completion of term as Managing Director of the Company.
2	Date of <del>Appointment/reappointment /cessation (as applicable) /reappointment</del> Term of appointment	April 30, 2025
3	Brief Profile (in case of appointment)	Not Applicable.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

### **Annexure – C**

#### **3) Appointment of Mr. Yugal Sikri (DIN: 07576560) as a Non-Executive Non-Independent Director:**

1	Reason for Change viz. Appointment, <del>re-appointment, resignation, removal, death or otherwise;</del>	Appointment as Non-Executive Non-Independent Director.
2	Date of <del>Appointment/reappointment /cessation (as applicable) /reappointment</del> Term of appointment	May 1, 2025
3	Brief Profile (in case of appointment)	<p>Mr. Yugal Sikri holds Master of Pharmacy Degree from IIT, BHU, Master of Marketing Management from Jamnalal Bajaj Institute of Management Studies and Certificates in Management from Thunderbird and Harvard Business Schools.</p> <p>Mr. Sikri is a senior pharma industry professional backed by over 35 years of rich and diverse experiences in managing successfully large businesses, building mega-brands and bringing in business turnarounds.</p> <p>He has been Chairman, Pharmaceutical Management at NMIMS School of Business</p>

	<p>Management, where he is credited with transforming its pharmaceutical management program, forging a strong academia-industry partnership and launching thought leadership initiatives.</p> <p>He has also been invited to be a mentor at Atal Incubation Center, a Government of India-NMIMS initiative, encouraging entrepreneurship amongst young start-ups. He was on the Board of RPG Life Sciences for past 2 years as an Independent Director.</p> <p>His work experiences come from senior leadership assignments at GlaxoSmithKline, Warner Lambert/ Pfizer, Novartis, Ranbaxy and RPGLS that includes Region Head of India, Srilanka and Nepal and Global Head of Marketing (Commercial functions) at Ranbaxy.</p>
--	--

#### **Annexure – D**

#### **4) Resignation of Mr. Ashok Nair (DIN: 07906710) as Senior Management Personnel of the Company:**

1	Reason for Change viz. <del>Appointment, re-appointment, resignation, removal, death or otherwise;</del>	Resignation as a Senior Management personnel of the Company member.
2	Date of <del>Appointment/reappointment/cessation</del> (as applicable) <del>/reappointment/</del> Term of <del>appointment</del>	April 30, 2025
3	Brief Profile (in case of appointment)	Not Applicable.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

**Annexure – E**

**5) Appointment of Mr. Ashok Nair (DIN: 07906710) as Managing Director:**

1	Reason for Change viz. Appointment, <del>re-appointment, resignation, removal, death or otherwise;</del>	Appointment as Managing Director of the Company.
2	Date of Appointment/ <del>reappointment/cessation (as applicable) /reappointment/</del> Term of appointment	May 1, 2025, Appointed for a period of 3 years subject to approval of the shareholders.
3	Brief Profile (in case of appointment)	<p>Mr. Nair is an established healthcare leader with 39 years of experience and successful track record of building new businesses and turning around existing ones. He has worked with a broad spectrum of companies, from mature ones to healthtech startups. His last corporate role was as the Managing Director of Abbott Primary Care.</p> <p>Through his long career, he worked with leading pharmaceutical companies such as Abbott, Torrent Pharma, Sun Pharma and Cipla; in areas such as sales, marketing, commercial and product management. He was also involved in formulating policy under the aegis of various industry bodies. More recently, he was a Co-Founder of WatchYourHealth, a B2B healthtech startup since June 2023. He also advised PE firms on healthcare topics.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Ashok Nair is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Mr. Ashok Nair has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

**Annexure – F**

**6) Appointment of M/s. Parikh Parekh & Associates as s Secretarial Auditor of the Company:**

1	Reason for Change viz. Appointment, <del>re-appointment, resignation, removal, death or otherwise;</del>	Appointment of M/s. Parikh Parekh & Associates, Peer Reviewed Firm of Company Secretary, (CP No.: 9511), as the Secretarial Auditor of the Company.
2	Date of Appointment/ <del>reappointment /cessation (as applicable) /reappointment/</del> Term of appointment	For 5 (five) consecutive years commencing from FY 2025-26 up to FY 2029-30.
3	Brief Profile (in case of appointment)	<p>M/s. Parikh &amp; Associates is a well-known firm of Practising Company Secretaries founded in 1987 and based in Mumbai. The firm has been Peer Reviewed and Quality Reviewed by the Institute of Company Secretaries of India (ICSI), ensuring the highest standards in professional practices.</p> <p>M/s. Parikh &amp; Associates has a team of 35 members including 10 partners and focussed on providing comprehensive professional services in corporate law, SEBI regulations, FEMA compliance, and allied fields, providing solutions to ensure regulatory adherence and operational efficiency.</p> <p>The firm provides its services to various prominent companies and their expertise has earned the trust of industry leaders across sectors like banking, manufacturing, pharmaceuticals, and public utilities.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.



**Independent Auditor's Report on the Quarterly and Year to Date Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To**  
**The Board of Directors of**  
**RPG Life Sciences Limited**

**Report on the audit of the Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date financial results of RPG Life Sciences Limited (the "Company") for the quarter ended March 31, 2025 and for the year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2025 and for the year ended March 31, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.





In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



# **S R B C & COLL P**

Chartered Accountants


## **Other Matter**

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

## **For S R B C & CO LLP**

Chartered Accountants

**ICAI Firm Registration Number:** 324982E/E300003



**per Aruna Kumaraswamy**

Partner

Membership No.: 219350

UDIN: **25219350BMMARV5358**

Place: Mumbai

Date: April 28, 2025



**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025**

Particulars	Quarter ended			Year ended	
	31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from Operations	14,309	17,271	12,699	65,343	58,205
2 Other Income	506	331	165	1,268	721
<b>3 Total Income (1+2)</b>	<b>14,815</b>	<b>17,602</b>	<b>12,864</b>	<b>66,611</b>	<b>58,926</b>
<b>4 Expenses</b>					
(a) Cost of Materials Consumed	2,689	3,019	2,803	11,026	12,065
(b) Purchases of Stock-in-Trade	2,122	2,270	1,492	9,514	6,118
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	61	322	(151)	861	270
(d) Employee Benefits Expense	3,160	2,871	3,208	12,614	13,215
(e) Finance Costs	18	12	14	62	45
(f) Depreciation and Amortisation Expense	537	546	449	2,143	1,707
(g) Other Expenses	3,728	3,873	3,275	15,363	13,722
<b>Total Expenses</b>	<b>12,315</b>	<b>12,913</b>	<b>11,090</b>	<b>51,583</b>	<b>47,142</b>
<b>5 Profit before exceptional items and tax (3-4)</b>	<b>2,500</b>	<b>4,689</b>	<b>1,774</b>	<b>15,028</b>	<b>11,784</b>
6 Exceptional items (Refer Note 3)	10,990	-	-	8,260	-
<b>7 Profit before tax</b>	<b>13,490</b>	<b>4,689</b>	<b>1,774</b>	<b>23,288</b>	<b>11,784</b>
<b>8 Income tax expenses</b>					
a. Current Tax	1,748	1,192	545	4,969	3,254
b. Deferred Tax	7	4	(95)	(5)	(236)
<b>Total tax expenses</b>	<b>1,755</b>	<b>1,196</b>	<b>450</b>	<b>4,964</b>	<b>3,018</b>
<b>9 Profit for the period (7-8)</b>	<b>11,735</b>	<b>3,493</b>	<b>1,324</b>	<b>18,324</b>	<b>8,766</b>
<b>10 Other Comprehensive Income</b>					
(i) Items that will not be reclassified to Profit or Loss	(154)	2	(82)	(147)	(75)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	39	(1)	22	37	19
<b>Other Comprehensive Income Net of Tax</b>	<b>(115)</b>	<b>1</b>	<b>(60)</b>	<b>(110)</b>	<b>(56)</b>
<b>11 Total Comprehensive Income for the period (9+10)</b>	<b>11,620</b>	<b>3,494</b>	<b>1,264</b>	<b>18,214</b>	<b>8,710</b>
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
13 Other Equity				51,730	36,162
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					
(a) Basic (in Rs.)	70.96	21.12	8.01	110.80	53.01
(b) Diluted (in Rs.)	70.96	21.12	8.01	110.80	53.01

SIGNED FOR IDENTIFICATION  
BY   
**SRBC & CO LLP**  
**MUMBAI**



**Statement of Assets and Liabilities as at March 31, 2025**

(Rs. in Lakhs)

Particulars	As at March 31, 2025	As at March 31, 2024
	Audited	Audited
<b>ASSETS</b>		
<b><u>Non-current assets</u></b>		
Property, plant and equipment (Including Right of use assets)	16,118	9,703
Capital work-in-progress	395	8,478
Other intangible assets	1,065	1,650
Intangible assets under development	1,211	1,153
Financial assets		
i. Investments	101	101
ii. Loans	17	19
iii. Other financial assets	43	43
Income Tax asset (Net)	156	122
Deferred tax assets (Net)	100	58
Other non-current assets	50	151
<b>Total non-current assets</b>	<b>19,256</b>	<b>21,478</b>
<b><u>Current assets</u></b>		
Inventories	9,298	10,100
Financial assets		
i. Investments	12,590	9,015
ii. Trade receivables	8,676	4,913
iii. Cash and cash equivalents	2,870	1,972
iv. Bank balances other than (iii) above	11,091	1,675
v. Other financial assets	579	103
Other current assets	1,421	2,031
<b>Total current assets</b>	<b>46,525</b>	<b>29,809</b>
<b>Total assets</b>	<b>65,781</b>	<b>51,287</b>
<b>EQUITY AND LIABILITIES</b>		
<b><u>Equity</u></b>		
Equity share capital	1,323	1,323
Other equity	51,730	36,162
<b>Total equity</b>	<b>53,053</b>	<b>37,485</b>
<b><u>Liabilities</u></b>		
<b><u>Non-current liabilities</u></b>		
Financial liabilities		
i. Other financial liabilities	291	303
Provisions	454	403
<b>Total non-current liabilities</b>	<b>745</b>	<b>706</b>
<b><u>Current liabilities</u></b>		
Financial liabilities		
i. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	366	503
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	7,573	6,599
ii. Other financial liabilities	1,763	3,982
Other current liabilities	670	523
Provisions	1,611	1,217
Current tax liabilities (Net)	-	272
<b>Total current liabilities</b>	<b>11,983</b>	<b>13,096</b>
<b>Total liabilities</b>	<b>12,728</b>	<b>13,802</b>
<b>Total equity and liabilities</b>	<b>65,781</b>	<b>51,287</b>

SIGNED FOR IDENTIFICATION  
BY   
S R B C & CO LLP  
MUMBAI






**Statement of Cash Flows for the year ended March 31, 2025**

(Rs. in Lakhs)

	Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
		Audited	Audited
<b>A</b>	<b>Cash Flow from operating activities</b>		
	Profit before income tax	23,288	11,784
	Adjustments for		
	<b>Add/(Less) :</b>		
	Depreciation and amortisation expenses	2,143	1,707
	Loss on account of fire incident (Net)	1,633	-
	Finance costs	62	45
	Profit on assignment of surplus leasehold land along with built-up structures	(10,018)	-
	Profit on disposal of property, plant and equipment	(120)	(1)
	Unrealised exchange rate difference	(28)	(10)
	Provision for doubtful debts and advances (Net)	(162)	270
	Interest received	(321)	(142)
	Gain on sale of investments	(221)	(105)
	Provisions no longer required and written back	(115)	-
	Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	(475)	(472)
		15,666	13,076
	<b>Working capital adjustments:</b>		
	(Increase) in trade receivables	(3,575)	(1,425)
	Decrease in financial assets - Loans	2	2
	(Increase) / Decrease in other financial assets	(76)	32
	Decrease / (Increase) in other current assets	610	(558)
	Decrease / (Increase) in inventories	619	(595)
	Increase in trade payables	954	633
	(Decrease) / Increase in other financial liabilities	(1,585)	1,338
	Increase / (Decrease) in provisions	299	(39)
	Increase / (Decrease) in other current liabilities	147	(97)
	<b>Cash generated from operations</b>	13,061	12,367
	Income taxes paid	(5,275)	(2,931)
	<b>Net cash inflow from operating activities</b>	7,786	9,436
<b>B</b>	<b>Cash flow from investing activities:</b>		
	Acquisition of property, plant and equipment and Intangible assets	(3,603)	(6,923)
	Proceeds from sale of property, plant and equipment	10,947	15
	Interim payment received from insurance claim	450	-
	Movement in Other bank balances (Net)	(9,416)	1,547
	Investment in Mutual Funds	(7,650)	(4,350)
	Proceeds from sale of Mutual fund	4,771	1,755
	Investment in unquoted equity shares	-	(101)
	Interest received	321	142
	<b>Net cash (outflow) from investing activities</b>	(4,180)	(7,915)
<b>C</b>	<b>Cash flow from financing activities</b>		
	Proceeds from/ (Repayment of) long term borrowings	-	(1)
	Interest paid	(62)	(45)
	Dividend paid	(2,646)	(1,985)
	<b>Net cash (outflow) from financing activities</b>	(2,708)	(2,031)
	<b>Net (decrease)/increase in cash and cash equivalents</b>	898	(510)
	Add: Cash and cash equivalents at the beginning of the financial year	1,972	2,482
	<b>Cash and cash equivalents at the end of the year</b>	2,870	1,972

SIGNED FOR IDENTIFICATION  
BY   
S R B C & CO LLP  
MUMBAI



**Notes:**


- The above results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on April 28, 2025.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.

3. Exceptional items:


(Rs. in Lakhs)

Exceptional Income / (Expenses)	Quarter ended			Year ended	
	31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
	Audited	Unaudited	Audited	Audited	Audited
Profit on assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai	12,623	-	-	9,893	-
Loss on account of fire incident - Refer note 3(a)	(1,633)	-	-	(1,633)	-
<b>Total exceptional items</b>	<b>10,990</b>	<b>-</b>	<b>-</b>	<b>8,260</b>	<b>-</b>

- 3(a) On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Company located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai – 400703, Maharashtra resulting in an impact on part of the Building, Plant & Machinery, inventories and other assets of the said manufacturing block. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in this incident. The assets impacted due to the fire incident are adequately covered under an insurance policy. The Company has performed a comprehensive analysis of the estimated loss arising on account of the fire incident for majority of the assets impacted by the fire and accordingly submitted a provisional insurance claim for the estimated loss. The insurance company has admitted the claim and has also released two tranches of interim payment aggregating Rs 850 lakhs. Based on such assessment, the Company has recognised an initial loss of Rs. 2,483 lakhs and a corresponding credit of the two tranches of interim payment of Rs. 850 lakhs resulting in net initial loss of Rs. 1,633 lakhs and the same has been presented as an exceptional item in the financial statements. The final amount of the approved claim from the insurance company will be determined based on the completion of the restoration activity of the said block, and net gain/loss, if any, would be accounted for in FY 2025-26.
- Figures of the quarter ended March 31, 2025 and March 31, 2024 are the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the relevant financial year which were subjected to limited review by Auditors.
- The Board of Directors has recommended a final dividend of Rs.20 (Rupees Twenty only) per equity share (250% on the face value of Rs 8 each) and additionally a special dividend of Rs.4 (Rupees Four only) per equity share (50% on the face value of Rs 8 each) on account of significant exceptional profit on assignment of land for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting.



For RPG Life Sciences Limited



Yugal Sikri  
Managing Director  
Mumbai, April 28, 2025

